KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ginkgo Bioworks Holdings (DNA) EBT Margin (2020 - 2025)

Ginkgo Bioworks Holdings' EBT Margin history spans 6 years, with the latest figure at 243.72% for Q4 2025.

  • For Q4 2025, EBT Margin rose 227.0% year-over-year to 243.72%; the TTM value through Dec 2025 reached 184.3%, up 5684.0%, while the annual FY2025 figure was 184.3%, 5684.0% up from the prior year.
  • EBT Margin reached 243.72% in Q4 2025 per DNA's latest filing, down from 207.93% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 63.76% in Q3 2024 to a low of 1081.31% in Q4 2021.
  • Average EBT Margin over 5 years is 352.27%, with a median of 244.86% recorded in 2024.
  • Peak YoY movement for EBT Margin: tumbled -93660bps in 2021, then soared 89018bps in 2022.
  • A 5-year view of EBT Margin shows it stood at 1081.31% in 2021, then skyrocketed by 82bps to 191.13% in 2022, then plummeted by -219bps to 609.67% in 2023, then surged by 60bps to 245.99% in 2024, then increased by 1bps to 243.72% in 2025.
  • Per Business Quant, the three most recent readings for DNA's EBT Margin are 243.72% (Q4 2025), 207.93% (Q3 2025), and 122.13% (Q2 2025).